Eterna Historical Income Statement
| ERNA Stock | USD 0.29 0.03 9.38% |
Historical analysis of Eterna Therapeutics income statement accounts such as Total Operating Expenses of 19.3 M or Depreciation And Amortization of 1.1 M can show how well Eterna Therapeutics performed in making a profits. Evaluating Eterna Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Eterna Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Eterna Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Eterna Therapeutics is a good buy for the upcoming year.
Eterna |
About Eterna Income Statement Analysis
Eterna Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Eterna Therapeutics shareholders. The income statement also shows Eterna investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Eterna Therapeutics Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Eterna Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Eterna Therapeutics. It is also known as Eterna Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Eterna Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Eterna Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from Eterna Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Eterna Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.At present, Eterna Therapeutics' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 7.3 M, whereas Total Revenue is forecasted to decline to about 64.6 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 74K | 30K | 614K | 644.7K | Depreciation And Amortization | 459K | 497K | 1.1M | 1.1M |
Eterna Therapeutics income statement Correlations
Click cells to compare fundamentals
Eterna Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eterna Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Revenue | 23.3M | 19.8M | 5.8M | 0.0 | 68K | 64.6K | |
| Gross Profit | 12.0M | (98K) | (459K) | (497K) | (168K) | (159.6K) | |
| Other Operating Expenses | 21.0M | 7.2M | 27.4M | 27.2M | 21.2M | 20.0M | |
| Operating Income | (1.2M) | (7.2M) | 68.3M | (33.2M) | (21.1M) | (20.1M) | |
| Ebit | (1.2M) | (7.2M) | (122.4M) | (33.7M) | (21.1M) | (22.1M) | |
| Total Operating Expenses | 13.2M | 7.2M | 27.4M | 27.2M | 20.7M | 19.3M | |
| Income Before Tax | (2.0M) | (7.3M) | (122.3M) | (24.5M) | (21.7M) | (20.6M) | |
| Total Other Income Expense Net | (808K) | (19.3M) | (95.1M) | 8.7M | (536K) | (562.8K) | |
| Net Income | (2.0M) | 11.9M | (122.3M) | (24.6M) | (21.7M) | (20.6M) | |
| Depreciation And Amortization | 3.2M | 98K | 459K | 497K | 1.1M | 1.1M | |
| Interest Expense | 249K | 43K | 74K | 30K | 614K | 644.7K | |
| Ebitda | 2.0M | (7.2M) | (121.9M) | (33.2M) | (19.9M) | (18.9M) | |
| Cost Of Revenue | 7.8M | 98K | 459K | 497K | 236K | 224.2K | |
| Income Tax Expense | 27K | (19.2M) | 5K | 45K | (3K) | (3.2K) | |
| Net Income Applicable To Common Shares | (8.9M) | (7.3M) | (122.6M) | (24.6M) | (22.1M) | (21.0M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.31) | Revenue Per Share 0.03 | Return On Assets (0.29) | Return On Equity (11.54) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.